Full View

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

P Montesinos, C Recher, S Vives… - … England Journal of …, 2022 - Mass Medical Soc
Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …
被引用次数：280 相关文章

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

P Montesinos, C Recher, S Vives… - The New England …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The combination of ivosidenib-an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)-and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

[引用][C] Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

P Montesinos, C Recher, S Vives… - New England Journal …, 2022 - oparu.uni-ulm.de
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia Toggle navigation
English Deutsch Deutsch English Deutsch Einloggen Toggle navigation Dokumentanzeige …

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

P Montesinos, C Recher, S Vives… - The New England …, 2022 - europepmc.org
Background The combination of ivosidenib-an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)-and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

[引用][C] Ivosidenib and Azacitidine inIDH1-Mutated Acute Myeloid Leukemia

P Montesinos, C Recher, S Vives, E Zarzycka… - New England Journal …, 2022 - cir.nii.ac.jp
Ivosidenib and Azacitidine in<i>IDH1</i>-Mutated Acute Myeloid Leukemia | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

[引用][C] Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

P Montesinos, C Recher, S Vives, E Zarzycka, J Wang… - 2022 - oparu.uni-ulm.de